Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 15/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | UBE2N | P61088 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18891800 | 0.89 | MAPK1 (0.49) | MAPK1ADORA2ASMN1; SMN2FSCN1CCNA2 | |
| SCHEMBL25970891 | 0.88 | MAPK1 (0.46) | MAPK1SMN1; SMN2HTTUBE2NFSCN1 | |
| SCHEMBL25970673 | 0.84 | MAPK1 (0.59) | MAPK1BRD4 | |
| SCHEMBL25970646 | 0.83 | MAPK1 (0.70) | MAPK1 | |
| SCHEMBL18860597 | 0.83 | MAPK1 (0.43) | MAPK1BRD4ADORA2ACCNA2CDK2 | |
| SCHEMBL25970674 | 0.83 | MAPK1 (0.71) | MAPK1 | |
| SCHEMBL18891654 | 0.80 | MAPK1 (0.72) | MAPK1ADORA2A | |
| SCHEMBL25970583 | 0.78 | GSK3B (0.47) | — | |
| SCHEMBL25970915 | 0.77 | MAPK1 (0.54) | MAPK1BRD4 | |
| SCHEMBL21557646 | 0.76 | MAPK1 (0.46) | MAPK1SMN1; SMN2HTTUBE2NFSCN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708364-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885BRD4 1103/4885ADORA2A 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.